Immutep logo
Immutep
IMMP | NASDAQ
Chart Builder DCF Calculator
$3.32
-$0.16 (-4.60%)
At close: Nov 16, 2026, 3:59 PM ET
$3.40
+$0.08 (+2.41%)
After-hours: Nov 16, 2026, 4:10 PM ET

Immutep Company Profile

Company profile explained

Company Profile

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Key Executives

Name Position
Marc Voigt Chief Executive Officer, MD, Chief Financial Officer, Chief Business Officer & Executive Director
Deanne Miller Chief Operating Officer, General Counsel & Joint Company Secretary
Christian Mueller Chief Development Officer
Frederic Triebel Chief Scientific Officer & Executive Director
Indira Naidu Joint Company Secretary
Stephan Winckels Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 29, 2026 6-K Filing
Oct 23, 2026 20-F Filing
Oct 14, 2026 6-K Filing
Sep 22, 2026 6-K Filing
Sep 11, 2026 6-K Filing
Sep 02, 2026 6-K Filing
Aug 03, 2026 6-K Filing
Jul 14, 2026 6-K Filing
Jun 05, 2026 6-K Filing
May 01, 2026 6-K Filing
View All SEC Filings ➞
Immutep
Immutep logo
Country Australia
IPO Date Apr 19, 2012
Industry Biotechnology
Sector Healthcare
Employees 53
CEO Marc Voigt

Contact Details

Australia Square Sydney, NSW 2000 Australia

Stock Details

Ticker Symbol IMMP
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001506184
CUSIP Number 45257L207
ISIN Number US45257L2079
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.